Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.

Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, Nölker G, Piccini JP, De Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L.

Eur Heart J. 2018 Aug 21;39(32):2942-2955. doi: 10.1093/eurheartj/ehy176.

2.

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.

Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ.

Europace. 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. Epub 2015 Oct 18. Review.

PMID:
26481149
3.

Variations of heart rate variability parameters prior to the onset of ventricular tachyarrhythmia and sinus tachycardia in ICD patients. Results from the heart rate variability analysis with automated ICDs (HAWAI) registry.

Wollmann CG, Gradaus R, Böcker D, Fetsch T, Hintringer F, Hoh G, Hatala R, Podczeck-Schweighofer A, Kreutzer U, Kamaryt P, Hauser T, Kersten JF, Wegscheider K, Breithardt G.

Physiol Meas. 2015 May;36(5):1047-61. doi: 10.1088/0967-3334/36/5/1047. Epub 2015 Apr 22.

PMID:
25903155
4.

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.

Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, Gillis A, Gulizia M, Hack G, Haegeli L, Hatem S, Häusler KG, Heidbüchel H, Hernandez-Brichis J, Jais P, Kappenberger L, Kautzner J, Kim S, Kuck KH, Lane D, Leute A, Lewalter T, Meyer R, Mont L, Moses G, Mueller M, Münzel F, Näbauer M, Nielsen JC, Oeff M, Oto A, Pieske B, Pisters R, Potpara T, Rasmussen L, Ravens U, Reiffel J, Richard-Lordereau I, Schäfer H, Schotten U, Stegink W, Stein K, Steinbeck G, Szumowski L, Tavazzi L, Themistoclakis S, Thomitzek K, Van Gelder IC, von Stritzky B, Vincent A, Werring D, Willems S, Lip GY, Camm AJ.

Europace. 2013 Nov;15(11):1540-56. doi: 10.1093/europace/eut232. Epub 2013 Aug 27.

PMID:
23981824
5.

Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T.

Circ Arrhythm Electrophysiol. 2012 Feb;5(1):43-51. doi: 10.1161/CIRCEP.111.965178. Epub 2011 Dec 7.

PMID:
22157519
6.

Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry.

Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R; DES.DE Study Group.

Clin Res Cardiol. 2011 Aug;100(8):701-9. doi: 10.1007/s00392-011-0301-8. Epub 2011 Mar 18.

PMID:
21416192
7.

Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Kuck KH; DES.DE Study Group.

Am J Cardiol. 2009 Nov 15;104(10):1362-9. doi: 10.1016/j.amjcard.2009.06.058. Epub 2009 Sep 26.

PMID:
19892051
8.

Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design.

Goette A, Breithardt G, Fetsch T, Hanrath P, Klein HU, Lehmacher W, Steinbeck G, Meinertz T.

Clin Drug Investig. 2007;27(10):697-705.

PMID:
17803345
9.

Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.

Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W, Breithardt G.

Am Heart J. 2005 Nov;150(5):899.

PMID:
16290956
10.

Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.

Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G; Prevention of Atrial Fibrillation after Cardioversion Investigators.

Eur Heart J. 2004 Aug;25(16):1385-94.

PMID:
15302102
11.

[Clinical register in cardiology and other indication fields].

Fetsch T, Fleck E, Frantz E.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Jun;47(6):563-4. German. No abstract available.

PMID:
15221107
12.

Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).

Stellbrink C, Hanrath P, Nixdorff U, Hofmann T, Lehmacher W, Kühle K, Fetsch T, Grewe R, Schmidt-Lucke JA; Anticoagulation in Cardioversion using Enoxaparin Study Group.

Z Kardiol. 2002 Mar;91(3):249-54.

PMID:
12001541
13.

[Atrial fibrillation successfully converted. A new standard in the prevention of recurrence?].

Fetsch T.

MMW Fortschr Med. 2001 Dec 13;143(51-52):10-2. German. No abstract available.

PMID:
11824159
14.

Prolonged QRS duration increases QT dispersion but does not relate to arrhythmias in survivors of acute myocardial infarction.

Kirchhof P, Eckardt L, Arslan O, Reinhardt L, Mönnig G, Fetsch T, Breithardt G, Borggrefe M, Haverkamp W.

Pacing Clin Electrophysiol. 2001 May;24(5):789-95.

PMID:
11388097
15.

Signal characteristics of multichannel epicardial electrograms in chronic ischaemic and scarred myocardium: electromechanical mismatch indicates viability in regions of myocardial dysfunction.

Bruns HJ, Janssen FW, Schäfers M, Hammel D, Fetsch T, Arslan O, Krenz M, Vahlhaus C, Borggrefe M, Scheld HH, Schober O, Breithardt G, Wichter T.

Basic Res Cardiol. 2001 Feb;96(1):98-105.

PMID:
11215538
16.

Emergency coronary artery bypass grafting after failed coronary angioplasty: what has changed in a decade?

Reinecke H, Fetsch T, Roeder N, Schmid C, Winter A, Ribbing M, Berendes E, Block M, Scheld HH, Breithardt G, Kerber S.

Ann Thorac Surg. 2000 Dec;70(6):1997-2003.

PMID:
11156109
17.

A new algorithm to determine complete isthmus conduction block after radiofrequency catheter ablation for typical atrial flutter.

Johna R, Eckardt L, Fetsch T, Breithardt G, Borggrefe M.

Am J Cardiol. 1999 Jun 15;83(12):1666-8, A6-7.

PMID:
10392874
18.

[Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study].

Fetsch T, Burschel G, Breithardt G, Engberding R, Koch HP, Lukl J, Trappe HJ, Treese N.

Z Kardiol. 1999 Mar;88(3):195-207. German.

PMID:
10355070
19.

Heart rate variability and electrical stability.

Fetsch T, Reinhardt L, Wichter T, Borggrefe M, Breithardt G.

Basic Res Cardiol. 1998;93 Suppl 1:117-24. Review. No abstract available.

PMID:
9833139
20.

Prediction of arrhythmia risk based on signal-averaged ECG in postinfarction patients.

Borggrefe M, Fetsch T, Martínez-Rubio A, Mäkijärvi M, Breithardt G.

Pacing Clin Electrophysiol. 1997 Oct;20(10 Pt 2):2566-76. Review.

PMID:
9358504
21.

Contribution of heart rate variability to long-term risk stratification after myocardial infarction.

Fetsch T, Reinhardt L, Breithardt G.

Eur Heart J. 1997 May;18(5):710-2. No abstract available.

PMID:
9152638
22.

Noninvasive risk modeling after myocardial infarction.

Reinhardt L, Mäkijärvi M, Fetsch T, Schulte G, Sierra G, Martínez-Rubio A, Montonen J, Katila T, Borggrefe M, Breithardt G.

Am J Cardiol. 1996 Sep 15;78(6):627-32.

PMID:
8831394
23.

Multiresolution decomposition of the signal-averaged ECG using the mallat approach for prediction of arrhythmic events after myocardial infarction.

Sierra G, Fetsch T, Reinhardt L, Martínez-Rubio A, Mäkijärvi M, Balkenhoff K, Borggrefe M, Breithardt G.

J Electrocardiol. 1996 Jul;29(3):223-34.

PMID:
8854333
24.

Reduced beat-to-beat changes of heart rate: an important risk factor after acute myocardial infarction.

Reinhardt L, Mäkijärvi M, Fetsch T, Martinez-Rubio A, Böcker D, Block M, Borggrefe M, Breithardt G.

Cardiology. 1996 Mar-Apr;87(2):104-11.

PMID:
8653725
25.

Heart rate variability in time domain after acute myocardial infarction.

Fetsch T, Reinhardt L, Mäkijärvi M, Böcker D, Block M, Borggrefe M, Breithardt G.

Clin Sci (Lond). 1996;91 Suppl:136-40.

PMID:
8813858
26.

Predictive value of wavelet correlation functions of signal-averaged electrocardiogram in patients after anterior versus inferior myocardial infarction.

Reinhardt L, Mäkijärvi M, Fetsch T, Montonen J, Sierra G, Martínez-Rubio A, Katila T, Borggrefe M, Breithardt G.

J Am Coll Cardiol. 1996 Jan;27(1):53-9.

27.

Prognosis and risk stratification after myocardial infarction.

Breithardt G, Borggrefe M, Fetsch T, Böcker D, Mäkijärvi M, Reinhardt L.

Eur Heart J. 1995 Aug;16 Suppl G:10-9. Review.

PMID:
8595793
28.

Comparison and combination of late potentials and spectral turbulence analysis to predict arrhythmic events after myocardial infarction in the Post-Infarction Late Potential (PILP) Study.

Mäkijärvi M, Fetsch T, Reinhardt L, Martinez-Rubio A, Shenasa M, Borggrefe M, Breithardt G.

Eur Heart J. 1995 May;16(5):651-9.

PMID:
7588897
29.

Are there gender differences in patients with coronary artery disease presenting with spontaneous sustained ventricular tachycardia and ventricular fibrillation?

Martinez-Rubio A, Borggrefe M, Shenasa M, Chen X, Wichter T, Fetsch T, Reinhardt L, Breithardt G.

Clin Cardiol. 1995 Mar;18(3):161-6.

30.

[Problems with anti-arrhythmia therapy in atrial fibrillation].

Breithardt G, Kottkamp H, Haverkamp W, Hindricks G, Fetsch T, Borggrefe M.

Z Kardiol. 1994;83 Suppl 5:63-9. Review. German.

PMID:
7846947
31.

Signal averaging in patients with coronary artery disease: how helpful is it?

Shenasa M, Fetsch T, Martínez-Rubio A, Borggrefe M, Breithardt G.

J Cardiovasc Electrophysiol. 1993 Oct;4(5):609-26. Review.

PMID:
8269326
32.

The signal-averaged ECG: time-domain analysis.

Breithardt G, Wichter T, Fetsch T, Seifert T, Borggrefe M, Shenasa M, Reinhardt L.

Eur Heart J. 1993 Sep;14 Suppl E:27-32. Review.

PMID:
8223752
33.

Late potentials, heart rate variability, and electrocardiography.

Böcker D, Shenasa M, Borggrefe M, Fetsch T, Breithardt G.

Curr Opin Cardiol. 1993 Jan;8(1):39-53. Review.

PMID:
10148087
34.

[Ventricular late potentials--methods and clinical importance].

Breithardt G, Fetsch T, Reinhardt L, Shenasa M, Borggrefe M.

Ther Umsch. 1992 Aug;49(8):550-8. Review. German.

PMID:
1519184
35.

New approaches to risk stratification after myocardial infarction.

Breithardt G, Borggrefe M, Fetsch T, Budde T.

J Cardiovasc Pharmacol. 1991;17 Suppl 6:S82-6. Review.

PMID:
1723125

Supplemental Content

Loading ...
Support Center